Main Article Content
Background: The significance of interleukin-10(IL-10) on the susceptibility of malignant tumor is one of the hot spots of current research. 1082A > G (rs1800896) and -819C > T (rs1800871) are two genetic variants of IL-10, and their effects on malignancy need to be further explored. Therefore, in order to further explore the relationship between IL-10 polymorphisms and cancer susceptibility and the role of IL-10 in the occurrence and development of malignant tumors, in this paper, we use of odds ratios (ORs), corresponding 95% confidence intervals (CIs), and in silico tools. analysis to study the relationship between the two. Furthermore, GSEA was used to analyze the expression of IL-10 in renal cell carcinoma, bladder cancer and prostate cancer. We conducted a systematic analysis of 50 controlled trials involving 15,418 cancer patients and 18,597 controls. The analysis showed that the -1082A>G (rs1800896) and -819C>T (rs1800871) polymorphism were associated with the risk of bladder cancer. GSEA showed that IL-10 was highly expressed through the Cytokine-Cytokine-receptor-interaction pathway, JSK-STAT-signaling pathway, Natural killer cell mediated cytotoxicity pathway and Leukocyte transendothelial migration pathway.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. Hsiao, J. R., Chang, C. C., Lee, W. T., Huang, C. C., Ou, C. Y., Tsai, S. T.,... & Chang, J. S. (2018). The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma. Carcinogenesis, 39(6), 778-787.
3. Lorenzo-González, M., Fernández-Villar, A., & Ruano-Ravina, A. (2019). Disentangling tobacco-related lung cancer—genome-wide interaction study of smoking behavior and non-small cell lung cancer risk. Journal of Thoracic Disease, 11(1), 10.
4. Spits, H., & de Waal Malefyt, R. (1992). Functional characterization of human IL-10. International archives of allergy and immunology, 99(1), 8-15.
5. Chow, M. T., Möller, A., & Smyth, M. J. (2012, February). Inflammation and immune surveillance in cancer. In Seminars in cancer biology (Vol. 22, No. 1, pp. 23-32). Academic Press.
6. Liang, L., Zhao, Y. L., Yue, J., Liu, J. F., Han, M., Wang, H., & Xiao, H. (2011). Interleukin-10 gene promoter polymorphisms and their protein production in pleural fluid in patients with tuberculosis. FEMS Immunology & Medical Microbiology, 62(1), 84-90.
7. Li, M., Yue, C., Zuo, X., Jin, G., Wang, G., Guo, H.,... & Zhao, X. (2020). The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province. PLoS One, 15(5), e0232174.
8. Shih, C. M., Lee, Y. L., Chiou, H. L., Hsu, W. F., Chen, W. E., Chou, M. C., & Lin, L. Y. (2005). The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung cancer, 50(3), 291-297.
9. Kumar, S., Kumari, N., Mittal, R. D., Mohindra, S., & Ghoshal, U. C. (2015). Association between pro-(IL-8) and anti-inflammatory (IL-10) cytokine variants and their serum levels and H. pylori-related gastric carcinogenesis in northern India. Meta Gene, 6, 9-16.
10. Ahirwar, D., Mandhani, A., & Mittal, R. D. (2009). Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Archives of medical research, 40(2), 97-102.
11. Plantinga, T. S., Costantini, I., Heinhuis, B., Huijbers, A., Semango, G., Kusters, B.,... & Netea-Maier, R. T. (2013). A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell–derived thyroid carcinoma. Carcinogenesis, 34(7), 1529-1535.
12. Howell, W. M., & Rose-Zerilli, M. J. (2006). Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Familial cancer, 5, 143-149.
13. Zou, Y. F., Wang, F., Feng, X. L., Tian, Y. H., Tao, J. H., Pan, F. M., & Huang, F. (2011). Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. European journal of cancer, 47(7), 1072-1079.
14. Faupel-Badger, J. M., Kidd, L. C. R., Albanes, D., Virtamo, J., Woodson, K., & Tangrea, J. A. (2008). Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes & Control, 19, 119-124.
15. Eder, Tanja., Mayer, Ramona., Langsenlehner, Uwe., Renner, Wilfried., & Krippl, Peter.. (2006). Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. European journal of cancer (Oxford, England : 1990), 43(3).
16. Turner, D., Williams, D. M., Sankaran, D., Lazarus, M., Sinnott, P. J., & Hutchinson, I. V. (1997). An investigation of polymorphism in the interleukin‐10 gene promoter. European journal of immunogenetics, 24(1), 1-8.
17. McCarron, S. L., Edwards, S., Evans, P. R., Gibbs, R., Dearnaley, D. P., Dowe, A.,... & Howell, W. M. (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer research, 62(12), 3369-3372.
18. Baştürk, B., Yavaşçaoğlu, İ., Vuruşkan, H., Göral, G., Oktay, B., & Oral, H. B. (2005). Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine, 30(1), 41-45.
19. Havranek, E., Howell, W. M., Fussell, H. M., Whelan, J. A., Whelan, M. A., & Pandha, H. S. (2005). An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. The Journal of urology, 173(3), 709-712.
20. Xu, J., Lowey, J., Wiklund, F., Sun, J., Lindmark, F., Hsu, F. C.,... & Grönberg, H. (2005). The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiology Biomarkers & Prevention, 14(11), 2563-2568.
21. Michaud, D. S., Daugherty, S. E., Berndt, S. I., Platz, E. A., Yeager, M., Crawford, E. D.,... & Hayes, R. B. (2006). Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer research, 66(8), 4525-4530.
22. Zabaleta, J., Lin, H. Y., Sierra, R. A., Hall, M. C., Clark, P. E., Sartor, O. A.,... & Ochoa, A. C. (2008). Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29(3), 573-578.
23. Cozar, J. M., Romero, J. M., Aptsiauri, N., Vazquez, F., Vilchez, J. R., Tallada, M.,... & Ruiz-Cabello, F. (2007). High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Human immunology, 68(8), 698-704.
24. Faupel-Badger, J. M., Kidd, L. C. R., Albanes, D., Virtamo, J., Woodson, K., & Tangrea, J. A. (2008). Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes & Control, 19, 119-124.
25. Ahirwar, D., Mandhani, A., & Mittal, R. D. (2009). Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Archives of medical research, 40(2), 97-102.
26. Kesarwani, P., Ahirwar, D. K., Mandhani, A., Singh, A. N., Dalela, D., Srivastava, A. N., & Mittal, R. D. (2009). IL-10− 1082 G> A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World journal of urology, 27, 389-396.
27. Omrani, M. D., Bazargani, S., & Bageri, M. (2008). Interlukin-10, interferon-γ and tumor necrosis factor-α genes variation in prostate cancer and benign prostatic hyperplasia. Current Urology, 2(4), 175-180.
28. VanCleave, T. T., Moore, J. H., Benford, M. L., Brock, G. N., Kalbfleisch, T., Baumgartner, R. N.,... & Kidd, L. C. R. (2010). Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. The Prostate, 70(4), 341-352.
29. Wang, M. H., Helzlsouer, K. J., Smith, M. W., Hoffman‐Bolton, J. A., Clipp, S. L., Grinberg, V.,... & Platz, E. A. (2009). Association of IL10 and other immune response‐and obesity‐related genes with prostate cancer in CLUE II. The Prostate, 69(8), 874-885.
30. Liu, J., Song, B., Bai, X., Liu, W., Li, Z., Wang, J.,... & Wang, Z. (2010). Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC cancer, 10(1), 1-7.
31. Oh, S. S., Chang, S. C., Cai, L., Cordon‐Cardo, C., Ding, B. G., Greenland, S.,... & Zhang, Z. F. (2010). Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers. International journal of cancer, 127(9), 2169-2182.
32. Niu WQ. (2011). Correlation analysis of IL-10 gene 1082A/G polymorphism with the development and progression of prostate cancer. International Journal of Laboratory Medicine, 32(1), 42-43.
33. Dluzniewski, P. J., Wang, M. H., Zheng, S. L., De Marzo, A. M., Drake, C. G., Fedor, H. L.,... & Platz, E. A. (2012). Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer RecurrenceImmune Response, Oxidation Genes, Prostate Cancer Recurrence. Cancer epidemiology, biomarkers & prevention, 21(10), 1774-1782.
34. Ianni, M., Porcellini, E., Carbone, I., Potenzoni, M., Pieri, A. M., Pastizzaro, C. D.,... & Licastro, F. (2013). Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer and Prostatic Diseases, 16(1), 56-61.
35. Chen ZG, Zhou W, Dai MJ, Wu ZG, & Jin R. (2013). Association of single nucleotide polymorphisms in the promoter region of IL-10 gene and smoking with bladder cancer. Chinese Journal of Epidemiology, 34(2), 183-186.
36. Dwivedi, S., Goel, A., Khattri, S., Mandhani, A., Sharma, P., Misra, S., & Pant, K. K. (2015). Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: an explorative study of prostate cancer patients in North Indian populations. Cytokine, 74(1), 117-122.
37. Horvat, V., Mandić, S., Mrčela, M., & Galić, J. (2015). Association of IL-1β and IL-10 polymorphisms with prostate cancer risk and grade of disease in Eastern Croatian population. Collegium antropologicum, 39(2), 393-400.
38. Miles, F. L., Rao, J. Y., Eckhert, C., Chang, S. C., Pantuck, A., & Zhang, Z. F. (2015). Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients. International Journal of Clinical and Experimental Medicine, 8(7), 11470.
39. Winchester, D. A., Till, C., Goodman, P. J., Tangen, C. M., Santella, R. M., Johnson‐Pais, T. L.,... & Platz, E. A. (2015). Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate, 75(13), 1403-1418.
40. Dwivedi, S., Singh, S., Goel, A., Khattri, S., Mandhani, A., Sharma, P.,... & Pant, K. K. (2015). Pro-(IL-18) and anti-(IL-10) inflammatory promoter genetic variants (intrinsic factors) with tobacco exposure (extrinsic factors) may influence susceptibility and severity of prostate carcinoma: a prospective study. Asian Pacific Journal of Cancer Prevention, 16(8), 3173-3181.
41. Chang, W. S., Liao, C. H., Tsai, C. W., Hu, P. S., Wu, H. C., Hsu, S. W.,... & Bau, D. T. (2016). The role of IL-10 promoter polymorphisms in renal cell carcinoma. Anticancer Research, 36(5), 2205-2209.
42. Bandil, K., Singhal, P., Dogra, A., Rawal, S. K., Doval, D. C., Varshney, A. K., & Bharadwaj, M. (2017). Association of SNPs/haplotypes in promoter of TNF A and IL-10 gene together with life style factors in prostate cancer progression in Indian population. Inflammation Research, 66, 1085-1097.
43. Winchester, D. A., Till, C., Goodman, P. J., Tangen, C. M., Santella, R. M., Johnson‐Pais, T. L.,... & Platz, E. A. (2017). Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. The Prostate, 77(8), 908-919.
44. Abbas, M., Mason, T., Ibad, A., Khraiwesh, M., Apprey, V., Kanaan, Y.,... & Brim, H. (2020). Genetic polymorphisms in IL-10 promoter are associated with smoking and prostate cancer risk in African Americans. Anticancer research, 40(1), 27-34